| Company Name: |
Chengdu anman biomedical technology co., LTD
|
| Tel: |
028-86617873 18113025300 |
| Email: |
yukijiangli@amanbio.com |
| Products Intro: |
Product Name:1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine hydrochloride
CAS:1902954-87-3
Purity:99% Package:1kg;10kg
|
| Company Name: |
Nanjing shengyilai Chemical Co., Ltd
|
| Tel: |
19951936396 |
| Email: |
3158688292@qq.com |
| Products Intro: |
Product Name:FEXUPRAZAN HCL
CAS:1902954-87-3
Purity:98% Package:1g;100g;1kg;100kg
|
|
| | DWP14012 hydrochloride Basic information |
| | DWP14012 hydrochloride Chemical Properties |
| storage temp. | -20°C, away from moisture | | form | Solid | | color | White to light yellow |
| | DWP14012 hydrochloride Usage And Synthesis |
| Biological Activity | Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H+, K+- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases[1].
The mechanism of action of Abeprazan hydrochloride is reversibly binding to H+, K+‐ATPase, and, unlike that of PPIs, does not require acidic environment for drug activation[1].
Abeprazan hydrochloride (DWP14012 hydrochloride) inhibits acid secretion in a dose-dependent manner and the inhibition of gastric acid secretion is equal to or greater than that of vonoprazan, a previously approved P-CAB, in various in vivo studies using pylorus-ligated rats, lumen-perfused rat models and heidenhain pouch dog models[1]. | | References | [1]. Sunwoo J, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. |
| | DWP14012 hydrochloride Preparation Products And Raw materials |
|